Older patients with acute decompensated HF are often physically frail, have a poor quality of life, and are frequently rehospitalised. Current guidelines fail to address physical functioning in older patients with acute decompensated HF. Accordingly, the REHAB-HF trial (NCT02196038) aimed to investigate the effects of a tailored, progressive rehabilitation programme in older adults who had been hospitalised for acute decompensated HF. Dr Dalane Kitzman (Wake Forest School of Medicine, NC, USA) presented the results.
The trial randomised 349 patients to either participate in the rehabilitation programme (n=175) or to receive usual care (n=174). The rehabilitation programme consisted of 36 sessions delivered over 12 weeks and encompassed endurance, mobility, strength, and balance training. The primary outcome was a change in short physical performance battery (SPPB) score, which was assessed at baseline and upon programme completion. The SPPB tests standing balance, walking, and strength.
At 3 months, the least-squares mean score on the SPPB score was 8.3 in the rehabilitation group and 6.9 in the usual care group. This yielded a mean between-group difference of 1.5 (95% CI 0.9–2.0; P<0.001).
The secondary outcome was all-cause rehospitalisation within 6 months. The rehospitalisation rate at 6 months was not significantly different between the 2 groups, with 1.18 in the rehabilitation group and 1.28 in the usual care group (rate ratio 0.93; 95% CI 0.66–1.19).
Authors of a New England Journal of Medicine Editorial editors declared that “the results presented by Kitzman and colleagues provide a compelling argument for the adoption of exercise rehabilitation as standard care, even for elderly, frail patients with acute heart failure” [3].
- Kitzman DW. A Novel Physical Rehabilitation Intervention for Older Patients with Acute Decompensated Heart Failure: The REHAB-HF Trial. ACC Scientific Session, 15–17 May 2021.
- Kitzman DW, et al. N Engl J Med 2021;May 16. DOI: 10.1056/NEJMoa2026141.
- Anker SD, Coats AJS. N Engl J Med Editorial 2021;May 16. DOI: 10.1056/NEJMe2106140.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Ibrutinib tied to worsening blood pressure, hypertension Next Article
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19 »
« Ibrutinib tied to worsening blood pressure, hypertension Next Article
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19 »
Table of Contents: ACC 2021
Featured articles
Electrophysiology
Favourable outcomes with transcatheter atrial appendage occlusion
Etripamil nasal spray significantly improves PSVT-related symptoms
Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
Heart Failure and Cardiomyopathy
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Novel use of ivabradine in reversible cardiomyopathy
Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy
Interventional and Structural Cardiology
Men and women benefit equally from early aspirin withdrawal following PCI
Similar outcomes with fractional flow reserve and angiography-guided revascularisation
TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI
Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI
Ischaemic Heart Disease
No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial
Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation
Moderate hypothermia not superior to mild hypothermia following out-of-hospital cardiac arrest
Better outcomes with invasive strategy if anatomic complete revascularisation is possible
Prevention and Health Promotion
STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids
Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia
Health equity and the role of the cardiologist: 7 priorities to consider
COVID-19
Dapagliflozin fails to show a significant protective effect in COVID-19
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Valvular Heart Disease
Apixaban outcomes similar to current standard of care following TAVR
Preliminary results encouraging for EVOQUE tricuspid valve replacement
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com